摘要
目的:观察比较吉西他滨联合顺铂(GP)和吉西他滨联合希罗达(GX)方案治疗晚期乳腺癌的临床疗效和毒副反应。方法:72例晚期乳腺癌患者被分为2组,并分别采用GP、GX方案化疗,其中GP组39例,GX组33例。GP组:吉西他滨1 000 mg/m2,静脉滴入,d1,d8;顺铂25 mg/m2,静脉滴入,d1～d3;21 d为1个周期。GX组:吉西他滨用法同GX组,希罗达2 500 mg/m2,分2次口服,d1～d14,21 d为1个周期,2个周期后评价疗效和毒副反应。结果:GP组和GX组总有效率(RR)分别为41%(16/39)和33%(11/33),差异无统计学意义,P>0.05;中位疾病进展时间分别为6.0、5.2个月,差异无统计学意义,P>0.05;中位生存期分别为12.8、12.0个月,差异无统计学意义,P>0.05。2组的主要毒副反应为骨髓抑制、胃肠道反应,其中GX组的手足综合征发生率明显高于GP组,胃肠道反应GP组明显高于GX组。结论:GP和GX方案对晚期乳腺癌有较好疗效,且毒副反应均可耐受,可作为蒽环类、紫杉类药物治疗失败的晚期乳腺癌的解救方案。
OBJECTIVE： To observe the efficacy and toxicity of GP and GX regimens in the treatment of the advanced breast cancer. METHODS： Totally 72 patients with advanced breast cancer were divided into two groups, and received GP or GX regimen. GP group（n=39） ： Gemcitabine 1 000 mg/m^2 ,dl, d8 ; DDP 25 mg/m^2 ,d1-d3 , iv. drip. GX group （n=33） ： Gemeitabine 1 000 mg/m^2 ,d1 , d8 ; Xeloda 2 500 mg/m^2 ,d1 - d14. And 21 days was a cycle. The efficacy and toxicity was evaluated after two cycles. RESULTS： The overall response rates in the GP and GX group were 41%（16/39） and 33% （11/33）, respectively （P〉0.05）. The median TTP of two group were 6.0 and 5.2 month （ P 〉 0. 05 ）. The median survival time was 12. 8 months and 12.0 months in the GP and GX group, respectively （P〉0.05）. The main toxicities in the two group were myelosuppression, gastrointestinal reaction and phlebitis. Hand-foot syndrome in GX was significantly higher than that in GP group, Gastrointestinal reactions in GP was significantly higher than that in GX group. CONCLUSION： GP and GX regimens are effective for patients with advanced breast cancer, their toxicities are tolerable, so they can be regarded as a ltermate regimens for anthracyclines and taxanes resistant patients with advanced breast cancer.
出处
《中华肿瘤防治杂志》
CAS
2011年第8期613-615,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
乳腺肿瘤
顺铂
蒽环类
药物疗法
联合
breast neoplasms
Cisplatin
anthracyclines
drug therapy, combination
